Indian pharmaceutical markets took a hit on Wednesday as investors reacted to President Trump’s aggressive proposal to impose a 100% tariff on generic drugs. The announcement triggered immediate volatility, leading to a significant dip in the Nifty Pharma index.
Companies with high export exposure to the United States are currently in the spotlight, as the potential policy would drastically alter profit margins. The Nifty 50 also struggled to maintain momentum amidst the broader sell-off in the healthcare sector.
Market analysts are advising a shift in strategy, suggesting that investors prioritize firms with a stronger focus on the domestic Indian market. By insulating portfolios from international trade barriers, shareholders may mitigate risks associated with shifting US trade regulations.
Despite the uncertainty, industry experts remain cautiously optimistic regarding future negotiations. Given India’s status as a critical global supplier of affordable medicines, diplomats and industry leaders are expected to push for exemptions to protect both the supply chain and consumer costs in the US.
